Carlo Ferrari

List of Publications by Year
in descending order

102 papers	12,935 citations	29994 54 h-index	30848 102 g-index
104 all docs	104 docs citations	104 times ranked	10380 citing authors

#	Article	IF	Citations
1	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic Tâ€“lymphocyte response. Nature Medicine, 1996, 2, 1104-1108.	15.2	804
2	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. Journal of Virology, 2007, 81, 4215-4225.	1.5	801
3	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine, 2000, 191, 1269-1280.	4.2	761
4	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. Journal of Virology, 2006, 80, 11398-11403.	1.5	521
5	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. Gastroenterology, 2010, 138, 682-693.e4.	0.6	416
6	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
7	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 2012, 61, 1754-1764.	6.1	387
8	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 7860-7867.	1.5	386
9	Adaptive immunity in HBV infection. Journal of Hepatology, 2016, 64, S71-S83.	1.8	358
10	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology, 1999, 117, 1386-1396.	0.6	331
11	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. Gastroenterology, 2012, 143, 963-973.e9.	0.6	308
12	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIVâ€“HCV International Panel. Aids, 2002, 16, 813-828.	1.0	280
13	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 2007, 45, 588-601.	3.6	266
14	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nature Medicine, 2017, 23, 327-336.	15.2	251
15	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology, 1994, 19, 286-295.	3.6	238
16	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. Cancer Research, 2006, 66, 1139-1146.	0.4	236
17	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Journal of Hepatology, 2003, 39, 595-605.	1.8	229
18	Kinetics of the immune response during HBV and HCV infection. Hepatology, 2003, 38, 4-13.	3.6	227

#	Article	IF	Citations
19	Interferon (IFN)â€“Î³â€“Inducible Proteinâ€“10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFNâ€Î±2a and Ribavirin for Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2006, 194, 895-903.	1.9	201
20	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 2006, 44, 1617-1625.	3.6	193
21	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology, 2006, 44, 126-139.	3.6	176
22	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. Journal of Virology, 2002, 76, 12423-12434.	1.5	168
23	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. Gastroenterology, 2010, 138, 1536-1545.	0.6	162
24	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine, 2007, 25, 8585-8597.	1.7	160
25	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. Gastroenterology, 2010, 138, 1931-1942.e2.	0.6	154
26	<scp>HBV</scp> and the immune response. Liver International, 2015, 35, 121-128.	1.9	153
27	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. Hepatology, 1999, 30, 1088-1098.	3.6	150
28	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2018, 68, 431-440.	1.8	147
29	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 250-257.	1.8	143
30	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2016, 65, 509-516.	1.8	142
31	Heterologous T cell immunity in severe hepatitis C virus infection. Journal of Experimental Medicine, 2005, 201, 675-680.	4.2	134
32	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	1.1	131
33	Hepatitis B virus immunopathology. Seminars in Immunopathology, 1995, 17, 261-81.	4.0	120
34	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. Gastroenterology, 2008, 134, 1470-1481.	0.6	115
35	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. Journal of Virology, 2008, 82, 10986-10997.	1.5	114
36	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. Journal of Hepatology, 2008, 48, 548-558.	1.8	113

#	Article	IF	Citations
37	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. Gastroenterology, 2012, 143, 1576-1585.e4.	0.6	106
38	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology, 2010, 51, 1523-1530.	3.6	105
39	The Hostâ€“pathogen Interaction during HBV Infection: Immunological Controversies. Antiviral Therapy, 2010, 15, 15-24.	0.6	96
40	Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. Gastroenterology, 2006, 130, 1098-1106.	0.6	87
41	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. Journal of Clinical Investigation, 2013, 123, 3766-3776.	3.9	80
42	Hepatitis B virus structure and biology. Microbial Pathogenesis, 1989, 6, 311-325.	1.3	78
43	Peginterferon-Î± does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. Journal of Hepatology, 2012, 56, 1239-1246.	1.8	75
44	Natural killer cell phenotype modulation and natural killer/Tâ€cell interplay in nucleos(t)ide analogueâ€treated hepatitis e antigenâ€negative patients with chronic hepatitis B. Hepatology, 2015, 62, 1697-1709.	3.6	73
45	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. Journal of Immunotherapy, 2008, 31, 271-282.	1.2	72
46	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. PLoS Pathogens, 2010, 6, e1001051.	2.1	72
47	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. Hepatology, 2002, 35, 1225-1236.	3.6	68
48	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 102-109.	1.8	66
49	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology, 2002, 36, 1446-1452.	3.6	66
50	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. Gastroenterology, 2012, 143, 78-87.e3.	0.6	63
51	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e32493.	1.1	61
52	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1â€“G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Annals of Surgical Oncology, 2016, 23, 981-989.	0.7	58
53	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology, 2005, 41, 826-831.	3.6	57
54	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. Journal of Immunology, 2005, 175, 7519-7529.	0.4	57

#	Article	IF	Citations
55	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 2007, 133, 1132-1143.	0.6	57
56	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut, 2012, 61, 1076-1084.	6.1	51
57	Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology, 1992, 103, 255-263.	0.6	50
58	Hepatitis C virus viremia following clinical resolution of acute hepatitis C. Journal of Hepatology, 1994, 20, 666-671.	1.8	49
59	Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgraduate Medical Journal, 2013, 89, 294-304.	0.9	49
60	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. Journal of Hepatology, 2017, 67, 543-548.	1.8	48
61	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virusâ€“Related Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 5465-5473.	3.2	46
62	Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology, 2001, 33, 1533-1543.	3.6	40
63	Bariatric Surgery in Patients with Inflammatory Bowel Disease: An Accessible Path? Report of a Case Series and Review of the Literature. Journal of Crohn's and Colitis, 2015, 9, 185-190.	0.6	40
64	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. OncoImmunology, 2016, 5, e1154249.	2.1	37
65	IL21R expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	1.7	36
66	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology, 2006, 43, 602-611.	3.6	35
67	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2009, 104, 605-616.	0.2	35
68	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Journal of Hepatology, 2013, 59, 221-228.	1.8	34
69	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 2012, 12, 11.	0.8	30
70	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 2008, 43, 73-80.	0.6	29
71	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Digestive and Liver Disease, 2011, 43, 259-265.	0.4	29
72	Modeling costâ€effectiveness and health gains of a â€œuniversalâ€•versus â€œprioritizedâ€•hepatitis C virus treatment policy in a realâ€life cohort. Hepatology, 2017, 66, 1814-1825.	3.6	25

#	Article	IF	Citations
73	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology, 1994, 19, 286-295.	3.6	21
74	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Digestive and Liver Disease, 2017, 49, 731-741.	0.4	19
75	Longâ€term followâ€up of antiâ€hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. Liver, 1992, 12, 94-99.	0.1	17
76	Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. Clinica Chimica Acta, 2013, 418, 59-62.	0.5	17
77	The Role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cerebrospinal Fluids for Screening of Acute Bacterial Meningitis. Clinical Laboratory, 2014, 60, 377-81.	0.2	16
78	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
79	Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. European Journal of Immunology, 2004, 34, 3208-3215.	1.6	14
80	T cell regulation in HBV-related chronic liver disease. Journal of Hepatology, 2017, 66, 1096-1098.	1.8	14
81	Evaluation of monoclonality of cell lines from sequential dilution assays. Journal of Immunological Methods, 1987, 105, 139-143.	0.6	13
82	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. Hepatology, 2004, 40, 289-299.	3.6	13
83	A method for measuring individual research productivity in hospitals: development and feasibility. BMC Health Services Research, 2015, 15, 468.	0.9	13
84	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.4	13
85	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2013, 8, e56991.	1.1	12
86	The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. Seminars in Immunopathology, 1990, 12, 25-31.	4.0	10
87	Is Steroid Therapy Needed in the Treatment of Destructive Thyrotoxicosis Induced by Î±-Interferon in Chronic Hepatitis C?. Hormone Research in Paediatrics, 2005, 63, 194-199.	0.8	10
88	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. International Journal of Oncology, 2016, 48, 1280-1289.	1.4	10
89	PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. Journal of Hepatology, 1994, 20, 47-56.	1.8	8
90	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. Seminars in Virology, 1996, 7, 23-30.	4.1	8

#	Article	IF	Citations
91	Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?. Gastroenterology, 2008, 134, 1601-1604.	0.6	7
92	Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-Î±2a/ribavirin therapy. Journal of Hepatology, 2008, 48, 932-938.	1.8	7
93	Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA. Amino Acids, 2019, 51, 1273-1288.	1.2	7
94	New perspectives for T-cell-based HCV vaccines. Journal of Hepatology, 2006, 45, 163-165.	1.8	6
95	T and B Cells in Hepatitis C Virus Control: What They Do and When They Fail. Gastroenterology, 2007, 132, 801-805.	0.6	6
96	Predicting treatment outcome following 24 weeks peginterferon Î±-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology, 2007, 45, 258-259.	3.6	6
97	Comparative pathogenesis of HBV and HCV. Virus Research, 2001, 82, 19-23.	1.1	5
98	Impact of disease severity on outcome of antiviral therapy in treatment-naÃ¯ve patients with chronic hepatitis C. Hepatology, 2007, 45, 1333-1334.	3.6	3
99	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	0.8	3
100	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. Journal of Medical Virology, 2016, 88, 843-851.	2.5	3
101	Missed treatment in an Italian HBV infected patients cohort: HBV RER. Digestive and Liver Disease, 2016, 48, 1346-1350.	0.4	2
102	Corrigendum to â€œRestoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatmentâ€•[J Hepatol 48 (2008) 548â€“558]. Journal of Hepatology, 2008, 49, 483.	1.8	0